Mirai Bio Advances Targeted LNP Delivery at ASGCT
CAMBRIDGE, Mass., April 27, 2026 Mirai Bio announced it will unveil two next-generation programs focused on targeted nucleic acid...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CAMBRIDGE, Mass., April 27, 2026 Mirai Bio announced it will unveil two next-generation programs focused on targeted nucleic acid...
NEW YORK, April 23, 2026 Biotia announced the publication of a pivotal clinical validation study in the Microbiology Spectrum...
EDMONTON, Alberta, April 20, 2026 Nanostics Inc. has announced the publication of a peer-reviewed study validating its AI-powered ClarityDX®...
Ingelheim, Germany, April 20, 2026 Boehringer Ingelheim has announced a major strategic expansion of its computational innovation capabilities with...
MILWAUKEE, Feb. 14, 2026 — New research presented at the AAAAI Annual Meeting 2026 demonstrates that machine learning (ML)...
Stanford, California, January 21, 2026 — Researchers at Stanford University announced in January 2026 the development of a machine-learning...
CAMBRIDGE, Mass. | January 8, 2026 — Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibody therapies, announced the...
SAN DIEGO | January 8, 2026 — Just – Evotec Biologics, a collaboration between Evotec SE and Just –...
Boston, December 18, 2025 — A revolutionary single-track data transformation approach is emerging as a powerful solution to one...
Dallas, Texas, October 30, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present two cutting-edge AI-driven drug-development...
